Actinium Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Actinium Pharmaceuticals, Inc. on December 27, 2013. The filing reports the completion of a private placement offering of equity securities to accredited investors.
Key Financial Metrics
The filing details a capital raise rather than operational financial performance. Key transaction metrics include:
- Gross Proceeds: $3,325,860
- Securities Issued: 554,310 shares of Common Stock and warrants to purchase 138,577 shares.
- Warrant Terms: Exercise price of $9.00 per share; exercisable for five years.
- Placement Agent Fees: $332,586 in cash plus warrants to purchase 69,289 shares.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is a transactional report, not a periodic financial statement.
Material Changes
The primary material change is the increase in equity capital and the dilution of existing shareholders due to the issuance of new shares and warrants. Additionally, the company entered into a Registration Rights Agreement and Lock-Up Agreements with officers and directors.
Outlook, Risks, and Contingencies
- Registration Obligation: The Company must register the shares and warrant shares with the SEC. Failure to file or declare the registration statement effective within the agreed timeframe triggers a penalty of 1% of the total purchase price per month, capped at 6% in the aggregate.
- Lock-Up Period: Officers and directors agreed not to sell or transfer their shares for six months following the effective date of the registration statement.
- Regulatory Status: Securities were sold under Rule 506 of Regulation D and have not been registered under the Securities Act of 1933.
Investor Verification Checklist
- Verify the effective date of the registration statement to determine the start of the 6-month lock-up period for insiders.
- Confirm the total number of outstanding shares post-issuance to assess dilution impact.
- Review the full text of the Purchase Agreement and Registration Rights Agreement (exhibits to the 10-K) for specific covenants and penalty triggers.
- Monitor the company's cash burn rate to understand how the $3.3 million in proceeds extends the operational runway.